immatics appoints Peter Chambré as Chairman
immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.
Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.
Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
AI tailors artificial DNA for future drug development - DNA molecules made-to-order: “What otherwise takes years is now shortened to weeks or days”
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Bacterial soundtracks revealed by graphene membrane - Have you ever wondered if bacteria make distinctive sounds?
BioNTech to Raise USD 250 Million in Private Placement - The private placement includes an investment in ordinary shares and a investment in 4-year mandatory convertible notes
Eurofins opens new faciltiy in Livingston
Improving therapies for GI tumors
Actelion submits the registration dossier for macitentan to EMA
ProtAffin AG strengthens Scientific Advisory Board
Study of skin biopsies offers potential as new diagnostic marker for Amyotrophic Lateral Sclerosis - The discovery of this biomarker detectable in small skin samples can be very useful for cases in which diagnosis is difficult
Memory in neural circuits
Fatal overproduction of antibodies - Mutations in plasma cells play a key role in light chain amyloidosis
